149 related articles for article (PubMed ID: 15886470)
1. Tapering and discontinuation of glucocorticoid prophylaxis during prolonged weekly to biweekly paclitaxel administration.
Braverman AS; Rao S; Salvatti ME; Adamson B; McManus M; Pierre S
Chemotherapy; 2005 May; 51(2-3):116-9. PubMed ID: 15886470
[TBL] [Abstract][Full Text] [Related]
2. Premedication strategy for weekly paclitaxel.
Quock J; Dea G; Tanaka M; Gandara D; Lara P; Lau D
Cancer Invest; 2002; 20(5-6):666-72. PubMed ID: 12197222
[TBL] [Abstract][Full Text] [Related]
3. [Administration of premedication with fexofenadine for paclitaxel-induced hypersensitive reactions in breast cancer patients complicated with closed-angle glaucoma].
Komatsubara K; Miyoshi K; Kogure Y; Matsuhisa T; Eguchi H
Gan To Kagaku Ryoho; 2010 Jan; 37(1):107-10. PubMed ID: 20087041
[TBL] [Abstract][Full Text] [Related]
4. Single-dose dexamethasone paclitaxel premedication.
Micha JP; Rettenmaier MA; Dillman R; Fraser P; Birk C; Brown JV
Gynecol Oncol; 1998 May; 69(2):122-4. PubMed ID: 9600818
[TBL] [Abstract][Full Text] [Related]
5. Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction.
Berger MJ; Vargo C; Vincent M; Shaver K; Phillips G; Layman R; Macrae E; Mrozek E; Ramaswamy B; Wesolowski R; Shapiro CL; Lustberg MB
Support Care Cancer; 2015 Jul; 23(7):2019-24. PubMed ID: 25519756
[TBL] [Abstract][Full Text] [Related]
6. [Evaluation of short-time premedication with d-chlorpheniramine maleate injection for paclitaxel-induced hypersensitivity reaction].
Harada T; Doi M; Yamada Y; Akase T
Gan To Kagaku Ryoho; 2008 Aug; 35(8):1347-51. PubMed ID: 18701846
[TBL] [Abstract][Full Text] [Related]
7. Intravenous prophylaxis for paclitaxel-related hypersensitivity reactions.
Bookman MA; Kloth DD; Kover PE; Smolinski S; Ozols RF
Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-13-S19-15. PubMed ID: 9427258
[TBL] [Abstract][Full Text] [Related]
8. [Paclitaxel hypersensitivity reactions in patients with advanced ovarian carcinoma].
Kobierski J; Majdak E; Mielcarek P; Emerich J
Ginekol Pol; 2002 Nov; 73(11):1015-20. PubMed ID: 12722392
[TBL] [Abstract][Full Text] [Related]
9. [A phase II study of weekly paclitaxel for advanced or recurrent breast cancer].
Wada Y; Otoshi M; Jitsuko A; Nishikawa H; Takahara S; Tsubono M; Imai S
Gan To Kagaku Ryoho; 2007 Jul; 34(7):1041-5. PubMed ID: 17637539
[TBL] [Abstract][Full Text] [Related]
10. [Weekly administration of low-dose paclitaxel for advanced or metastatic breast cancer].
Uno Y; Hirano M; Murakami N; Kikuchi T; Nozawa H; Okuda T; Oya J; Kikkawa H
Gan To Kagaku Ryoho; 2002 Feb; 29(2):227-32. PubMed ID: 11865628
[TBL] [Abstract][Full Text] [Related]
11. Paclitaxel administered by a 1-hour infusion: A phase I-II trial comparing two schedules.
Hainsworth JD; Raefsky EL; Greco FA
Cancer J Sci Am; 1995; 1(4):281-7. PubMed ID: 9166489
[TBL] [Abstract][Full Text] [Related]
12. Paclitaxel and simultaneous radiation in locally advanced stage IIIA/B non-small cell lung cancer: a clinical phase I study.
Vogt HG; Kolotas C; Martin T; Schneider LV; Goes-Schmieder R; Mitrou PS; Diergarten K; Kober B; Zamboglou N
Semin Oncol; 1996 Dec; 23(6 Suppl 16):120-3. PubMed ID: 9007138
[TBL] [Abstract][Full Text] [Related]
13. Prophylaxis for paclitaxel hypersensitivity reactions.
Kintzel PE
Ann Pharmacother; 2001 Sep; 35(9):1114-7. PubMed ID: 11573863
[TBL] [Abstract][Full Text] [Related]
14. The feasibility of dexamethasone omission in weekly paclitaxel treatment for breast cancer patients.
de Castro Baccarin AL; Irene MN; de Iracema Gomes Cubero D; Luz AS; Castro SN; Sordi R; Móz LES; Del Giglio A
Support Care Cancer; 2019 Mar; 27(3):927-931. PubMed ID: 30069696
[TBL] [Abstract][Full Text] [Related]
15. [Weekly administration of paclitaxel for advanced or metastatic breast cancer--short-course premedications for outpatients].
Kimura M; Koida T; Yanagita Y
Gan To Kagaku Ryoho; 2000 Oct; 27(11):1703-8. PubMed ID: 11057321
[TBL] [Abstract][Full Text] [Related]
16. [A case successfully treated by desensitization for paclitaxel-associated hypersensitivity reactions].
Yamatoya Y; Wada Y; Sato S; Morikawa T; Sakata N; Nakata J; Seki K; Wada N; Kamiyama K; Tominaga T
Gan To Kagaku Ryoho; 2007 Feb; 34(2):271-4. PubMed ID: 17301542
[TBL] [Abstract][Full Text] [Related]
17. Randomized, Controlled Trial of Dexamethasone Versus Dexamethasone Plus Hydrocortisone as Prophylaxis for Hypersensitivity Reactions Due to Paclitaxel Treatment for Gynecologic Cancer.
Jeerakornpassawat D; Suprasert P
Int J Gynecol Cancer; 2017 Oct; 27(8):1794-1801. PubMed ID: 28704328
[TBL] [Abstract][Full Text] [Related]
18. An effective and more convenient drug regimen for prophylaxis against paclitaxel-associated hypersensitivity reactions.
Markman M; Kennedy A; Webster K; Peterson G; Kulp B; Belinson J
J Cancer Res Clin Oncol; 1999 Jul; 125(7):427-9. PubMed ID: 10394964
[TBL] [Abstract][Full Text] [Related]
19. Oral premedication for the prevention of hypersensitivity reactions to paclitaxel.
Zidan J; Hussein O; Abzah A; Tamam S; Farraj Z; Friedman E
Med Oncol; 2008; 25(3):274-8. PubMed ID: 18363113
[TBL] [Abstract][Full Text] [Related]
20. Preliminary experience with a modified premedication protocol that included intravenous diphenhydramine and calcium bromide for the prophylaxis of paclitaxel-related hypersensitivity reactions.
Sasada S; Hirashima T; Nakamura Y; Takimoto T; Furukawa M; Kobayashi M; Nitta T; Matsui K; Kawase I
Int J Clin Oncol; 2007 Aug; 12(4):274-8. PubMed ID: 17701006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
